Corrigendum to "Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life" [Eur J Cancer 176 (2022) 88-99].

Thomas U Schulz Sarah Zierold Michael M Sachse Giulia Pesch Dirk Tomsitz Katharina Schilbach Katharina C Kähler Lars E French Lucie Heinzerling

Eur J Cancer

Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany; Side Effect Registry Immuno-Oncology SERIO, Munich, Germany; Department of Dermatology, University Hospital Erlangen, Erlangen, Germany. Electronic address:

Published: January 2025

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.ejca.2025.115236	DOI Listing

Publication Analysis

Top Keywords

corrigendum "persistent

"persistent immune-related

immune-related adverse

adverse events

events cessation

cessation checkpoint

checkpoint inhibitor

inhibitor therapy

therapy prevalence

prevalence impact

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!